EXPERTISE
GLP-1 Receptor Antagonist
GLP-1 Receptor Antagonist
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications that mimic the action of glucagon-like peptide-1, a hormone that stimulates insulin secretion in response to meals, inhibits glucagon release, and slows gastric emptying. These drugs are used to improve blood sugar control in adults with type 2 diabetes and help treat obesity. Commonly known GLP-1 receptor agonists include trade names such as Ozempic (semaglutide), Byetta (exenatide), Victoza (liraglutide), Trulicity (dulaglutide), and Rybelsus (oral semaglutide). They work by binding to GLP-1 receptors on pancreatic beta cells, thereby enhancing insulin secretion and suppressing the release of glucagon, which helps lower blood glucose levels.
The benefits of GLP-1 receptor agonists include significant reductions in HbA1c levels, which measure long-term blood glucose control, and weight loss, as these medications can decrease appetite and promote satiety. Additionally, some GLP-1 receptor agonists have been shown to have cardiovascular benefits, reducing the risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. However, there are risks associated with these medications, including gastrointestinal side effects such as nausea, vomiting, and diarrhea. There is also a risk of pancreatitis and, rarely, kidney injury or thyroid C-cell tumors, which necessitate careful patient selection and monitoring.
